EGFR-IN-33
EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) [1].
Product Specifications
CAS Number
2711105-59-6
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-in-33.html
Solubility
10 mM in DMSO
Smiles
C=CC(N1CCCC(C1)C2=CN(C3=C(N=CN=C23)N)C4=CC=C(C(Cl)=C4)OCC5=CC=CC=N5)=O
Molecular Formula
C26H25ClN6O2
Molecular Weight
488.97
References & Citations
[1]Yihan Wang, et al. Substituted acrylamide derivatives and compositions thereof and their uses. Patent WO2021185348A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD31 / PECAM-1 (Endothelial Cell Marker) (C31/1395R), 0.2mg/mL
